1. Identification of early-induced broadly neutralizing activities against transmitted founder HIV strains
- Author
-
Julie Lucas, Li-Yun Lin, Nicodème Paul, Géraldine Laumond, Jéromine Klingler, Sylvie Schmidt, Julia Frappier, Asma Essat, Laurence Meyer, Alicia Castro Gordon, C.é.cile Goujard, Seiamak Bahram, Christiane Moog, Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fédération Hospitalo-Universitaire (OMICARE), Centre de Recherche d’Immunologie et d’Hématologie [Strasbourg], Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg (UNISTRA), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Bicêtre, Nouvel Hôpital Civil de Strasbourg, Vaccine Research Institute (VRI), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), 3.2 TRIDIAG, European Commission, EC, Agence Nationale de la Recherche, ANR, Institut National de la Santé et de la Recherche Médicale, Inserm, Institut Universitaire de France, IUF, European Regional Development Fund, ERDF, We thank all participants of the ANRS PRIMO cohort. This work was granted by the ANRS (Agence Nationale de Recherches sur le SIDA et les hépatites virales), the Investissements d’Avenir program managed by the ANR under reference ANR-10-LABX-77 and EHVA (No. 681032, Horizon 2020). Work in S.B.'s laboratory is supported by grants from the Agence Nationale de la Recherche (ANR) (ANR-11-LABX-0070_TRANSPLANTEX), the INSERM (UMR_S 1109), the Institut Universitaire de France (IUF), all the University of Strasbourg (IDEX UNISTRA), the European regional development fund (European Union) INTERREG V program (project no. 3.2 TRIDIAG) and MSD-Avenir grant AUTOGEN. The funders had no role in study design, data collection and interpretation or the decision to submit the work for publication., and European Project: 681032,H2020,H2020-PHC-2015-single-stage_RTD,EHVA(2016)
- Subjects
transmitted/founders ,Infectious Diseases ,vaccine ,Immunology ,HIV ,Humans ,Immunology and Allergy ,neutralizing antibodies ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,HIV Infections ,acute infection ,Broadly Neutralizing Antibodies - Abstract
International audience; Objectives:Broadly neutralizing antibodies have been proposed as key actors for HIV vaccine development. However, they display features of highly matured antibodies, hampering their induction by vaccination. As protective broadly neutralizing antibodies should be induced rapidly after vaccination and should neutralize the early-transmitted founder (T/F) viruses, we searched whether such antibodies may be induced following HIV infection.Design:Sera were collected during acute infection (Day 0) and at viral set point (Month 6/12) and the neutralizing activity against T/F strains was investigated. Neutralizing activity in sera collected from chronic progressor was analyzed in parallel.Methods:We compared neutralizing activity against T/F strains with neutralizing activity against non-T/F strains using the conventional TZM-bL neutralizing assay.Results:We found neutralizing antibodies (nAbs) preferentially directed against T/F viruses in sera collected shortly after infection. This humoral response evolved by shifting to nAbs directed against non-T/F strains.Conclusion:Although features associated with nAbs directed against T/F viruses need further investigations, these early-induced nAbs may display lesser maturation characteristics; therefore, this might increase their interest for future vaccine designs.
- Published
- 2022
- Full Text
- View/download PDF